Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight reductions, with average losses approaching or exceeding ~20% at higher doses in adults with obesity who did not have diabetes, numbers that markedly exceed historical pharmacotherapy benchmarks
J Clin Invest 60: 716-723
However, significant results are typically observed over several months, with continued improvement as you stay on the treatment plan
Available from: Bao X, Qian K, Yao P
US$ 27.34
US$ 29.84
US$ 20.64
US$ 22.32
US$ 21.86
US$ 21.38
US$ 21.76
US$ 22.17
US$ 22.57
